Company Website

Contacts

Joseph Harcharik
Jharcharik@natera.com
515-491-8079

Virtual Exhibit Hall Home

Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessments in patients previously diagnosed with cancer. The test is available for both clinical and research use, and has been granted Breakthrough Device Designations by the FDA for multiple cancer types and indications. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor. This maximizes accuracy for detecting the presence or absence of residual disease in a blood sample, even at levels down to the single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to detect recurrence earlier and to help optimize treatment decisions.
 

Additional Information

Signatera CRC

Immunotherapy Monitoring